February 4, 2022

Dear Colleagues,

I want to reiterate how excited I am to be here at Yale Cancer Center and Smilow Cancer Hospital and to have the opportunity to join such a tremendous team of leaders in the oncology field. I have spent the last several months getting to know many of you and still have so much to learn over the coming months. As I finish my first week here in New Haven and at Yale, I want to thank everyone for the gracious welcome. I am especially grateful to Nita Ahuja, MD, MBA, for her thoughtful leadership of our Cancer Center and Smilow Cancer Hospital over the last year, and guidance as I began my transition to Yale.

Today, on World Cancer Day, we all recognize the tremendous toll that cancer takes on our community, our country, and around the globe. I believe that if we work together, Yale Cancer Center and Smilow Cancer Hospital can have an ever-greater impact on all forms of cancer. On a daily basis we can provide the best possible clinical care, and at the same time we will continue our efforts to conduct the most innovative and significant research.

Warm regards,
Eric P. Winer, MD

Announcements

Mark Lemmon Appointed Deputy Director of Yale Cancer Center
Please join me in welcoming Mark A. Lemmon, PhD, FRS, David A. Sackler Professor of Pharmacology, Professor of Molecular Biophysics and Biochemistry, and Co-Director of the Cancer Biology Institute, to his position of Deputy Director of Yale Cancer Center. Dr. Lemmon joined Yale Cancer Center in 2015 to bring the concept of the Cancer Biology Institute (CBI) on Yale West Campus to reality. He has assembled a team of basic science faculty in the Institute who are all members of Cancer Center research programs and are developing an exciting environment for interdisciplinary cancer research. Dr. Lemmon’s efforts to enhance
interdisciplinary cancer research. Dr. Lemmon's efforts to enhance interactions between basic, translational, population, and clinical investigators across the Cancer Center community in his former role as Associate Cancer Center Director for Basic Science, have strengthened research collaborations. These interactions will continue to flourish through his new leadership position as Deputy Director.

Dr. Lemmon is a graduate of Oxford University and earned his PhD from Yale University. His laboratory’s research focuses on understanding the signaling networks controlled by cancer-causing receptor tyrosine kinases using cellular, biochemical, and structural approaches. In 2016, he was elected as a Fellow of the Royal Society, the United Kingdom’s national science academy, and in 2019, Dr. Lemmon received the Yale Cancer Center Research Prize for Basic Science in recognition of his paper in *Cell*, “EGF Receptor Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics.”

Daniel D. DiMaio, MD, PhD
Appointed Senior Advisor to the Director

I am extremely grateful that after 11 years as Deputy Director of Yale Cancer Center, Daniel C. DiMaio, MD, PhD, Waldemar Von Zedtwitz Professor of Genetics and Professor of Molecular Biophysics and Biochemistry and of Therapeutic Radiology, has agreed to continue to share his knowledge and expertise as a Senior Advisor to the Director. For years, Dr. DiMaio’s vision, commitment, and support of our entire leadership team has been invaluable. His guidance during our Cancer Center Support Grant (CCSG) submissions and his historical knowledge of our Cancer Center are indispensable. Dr. DiMaio’s continued dedication to the success of our Cancer Center is greatly appreciated, and I look forward to continuing our work together.

Megan C. King, PhD, Named Associate Cancer Center Director for Basic Science

Megan C. King, PhD, Associate Professor of Cell Biology and of Molecular, Cellular, and Development Biology, has been appointed to the position of Associate Cancer Center Director for Basic Science. Dr. King has served as Co-Leader of our Radiobiology & Radiotherapy Research Program since 2019. In her new role as Associate Cancer Center Director for Basic Science, Megan will oversee YCC basic science priorities.
oversee YCC basic science priorities across the YCC community. Dr. King’s own research is generating unique insights into chromatin organization and dynamics, with a focus on DNA repair and the biology of BRCA cancer susceptibility genes.

### Department of Therapeutic Radiology Welcomes Two Faculty

The Department of Therapeutic Radiology is pleased to announce that Gabrielle W. Peters, MD, and Timothy Robinson, MD, PhD, will join the Smilow Radiation Oncology team. Dr. Peters will practice at the Smilow Cancer Hospital Care Centers in Guilford and Trumbull beginning in July following completion of her residency in radiation oncology at Smilow Cancer Hospital/Yale Cancer Center where she currently serves as the Education Chief Resident. She has been a leader in her residency and an advocate for patients throughout her training.

Dr. Peters received her medical degree from Creighton University School of Medicine in 2017 and was chosen to be inducted into Alpha Omega Alpha. During her training at Yale, she opened an investigator-initiated trial for lung cancer and received grant funding through the Radiological Society of North America for her work in medical education. Her research interests include medical education and improving clinical outcomes for patients with cancer. Her clinical practice will include thoracic, head and neck, genitourinary, and gastrointestinal malignancies.

Dr. Robinson will join Yale Cancer Center and Smilow Cancer Hospital in April from Moffitt Cancer Center in Tampa, FL where he is currently an Assistant Member in Radiation Oncology and Biostatistics and Bioinformatics and section head of Hematologic Malignancies and Cellular Therapeutics.

Dr. Robinson received his medical degree from Duke University School of Medicine in 2011, where he also received his PhD in Molecular Cancer Biology. He has a clinical research program focused on the emerging field of adaptive therapy in treating hematologic malignancies and solid tumors.
research program focused on the emerging roles of therapeutic radiation in hematologic and secondary CNS malignancies in combination with CAR T-cell and other immune-based therapies. His translational research program is focused on the role of alternative splicing in cancer, particularly with respect to its role in mediating cellular and immune therapy resistance. His clinical practice will focus on building an inpatient and metastasis service at Smilow Cancer Hospital, along with participating in the Spine Oncology and Hematology Programs.

**Joseph Kim, MD, Named Director of Prostate Cancer Research**

Joseph W. Kim, MD, Associate Professor of Internal Medicine (Medical Oncology), has been named Director of Prostate Cancer Research as part of the Prostate and Urologic Cancers DART. Dr. Kim has been a member of Yale Cancer Center and Smilow Cancer Hospital since 2013 and specializes in early phase clinical trials of novel cancer therapies and cares for patients with prostate cancer, urinary tract and bladder cancer, penile cancer, testicular cancer, and other genitourinary malignancies. Dr. Kim’s research interests include DNA repair pathway, mTOR pathway, tumor hypoxia, and cancer immunotherapy.

In this new role, Dr. Kim will be responsible for organizing the prostate cancer clinical and translational research and will be working under the direction of Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, and leader of the DART. Please join us in congratulating Dr. Kim on this new leadership role and we look forward to his continued contributions to the culture of innovation and discovery at Yale Cancer Center and Smilow Cancer Hospital.

**Notables**

**Cary Gross, MD,** Professor of Medicine (General Medicine) and of Epidemiology (Chronic Diseases); Founder and Director, Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, has been named **Associate Editor of JAMA Internal Medicine.**

**Donald Engelman, PhD,** the Eugene Higgins Professor of Molecular Biophysics and Biochemistry and a member of Yale Cancer Center’s Developmental Therapeutics Research Program, has been named a **Fellow of the American Association for the Advancement of Science (AAAS).**
The Genetics, Genomics, and Epigenetics Research Program at Yale Cancer Center welcomes Binyam Mogessie, PhD, Assistant Professor of Molecular, Cellular and Developmental Biology. Dr. Mogessie’s research focuses on understanding the cytoskeletal basis of chromosome segregation which are altered in human cancers and infertility. He has a strong track record of pursuing innovative research that is advancing areas of biology highly relevant to basic mechanisms of cell function and human disease. Dr. Mogessie’s research and teaching principles reflect his commitment to sharing with other Black scientists and underrepresented groups invaluable experiences which have critically helped him to transcend artificial barriers in science and society.

Please join Yale Cancer Center as we host the Yale School of Medicine Cancer Student Interest Group for our annual, virtual research “speed-dating” event—like last year’s event. Over the course of a few evenings in...
During the first week of March, we will gather a limited number of faculty and students via Zoom to give students interested in cancer a chance to meet one-on-one with a faculty member for about 10 minutes to hear about their research. When time is up, the students will shift breakout rooms to meet another faculty member. This event is a great opportunity to meet medical students who are looking to be research mentors as well as learn more about 5th year and summer internship opportunities.

Spots are limited so please confirm your interest in attending and your availability for the proposed dates by completing this SURVEY no later than Friday, February 18.

---

**Diversity, Equity, and Inclusion**

**Pamela Kunz, MD,** Associate Professor of Medicine (Medical Oncology) and Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, has been named to the [National Cancer Institute Equity Council EIP Subcommittee](#). The subcommittee’s primary charge is to understand the composition of, and make recommendations to improve the representation of, women and under-represented groups in leadership positions across the NCI clinical trial enterprise, including the NCI National Clinical Trials Network, NCI Community Oncology Research Program, and the Scientific Steering Committees.

**National Women Physicians Day**

Yesterday we honored National Women Physicians Day, a day that marks the birthday of Dr. Elizabeth Blackwell (1821-1910), the first woman to earn her medical degree in the United States. We celebrate the many women physicians throughout Yale Cancer Center and Smilow Cancer Hospital. They each play multifaceted roles as clinicians, scientists, educators, leaders, mentors, mothers, daughters, sisters, partners, friends, and more.

The field of medicine has historically been dominated by men. Although similar numbers of men and women are now enrolling in medical school, women physicians still face challenges and obstacles that make it difficult to stay in medicine and rise to leadership roles. At Yale Cancer Center, we want to embrace a culture that recruits and retains women, including women of color, and those who identify with other marginalized characteristics. Diversity truly makes us all better.


---

**Employee Profile: Kathleen Simon**

Kathy Simon is a New Patient Onboard Specialist for the Smilow Cancer Hospital Care Center. Her role is to assist our patients in their journey to their first appointment and our services to all of our patients who are from all disease backgrounds. It’s certainly a mission for Yale Cancer Center. Anne Chiang, MD, PhD, on her role as Deputy Chief Medical Officer & Chief Integration Officer for Smilow Cancer Hospital.

---

Watch Now

"If it were not for you giving all that blood, I would not be here." — Nicole Donzello, a patient at Smilow Cancer Hospital, talks about the urgent need for blood donations to support patients with cancer during a news conference at Yale New Haven Hospital with American Red Cross Connecticut.

---

Read More

Gilda’s Club Westchester has honored D. Barry Boyd, MD, MS, Assistant Professor of Medicine (Medical Oncology) at the Smilow Cancer Hospital Care Center in Greenwich, with the inaugural Spirit of Excellence in Oncology Award for his incredible contributions to the field of oncology. The Club recognized Dr. Boyd for the care he gave to Gilda Radner and the thousands of patients with cancer over the past 20+ years and for his support of the Gilda’s Club mission through our Professional Advisory Board.

Congratulations, Dr. Boyd, and thank you for your care of our patients!
Smilow Cancer Hospital Care Centers in Trumbull and Fairfield, and is responsible for scheduling newly diagnosed patients for their initial visit, and making sure they have everything they need ahead of the visit. She spends much of her day on the phone tracking down records from referring providers, and scheduling scans as needed, but remains a point of contact for patients until they are fully settled into the Smilow Network.

Working with two nurse coordinators and their assigned providers, Kathy triages patients and schedules them for their first visit. She also schedules patients into the newly developed Next Day Access Program, which was piloted last year and offers next-day access, reduced wait times for treatment, and increased patient satisfaction. On a daily basis, Kathy interacts with approximately 30 patients between both offices. She has been in this role for three years but has been in the medical field much longer. Kathy worked at a Cardiothoracic group for 15 years before moving to medical oncology where she continues to make a significant impact on the patient experience.

“I love this field and the patient population that I work with,” said Kathy. “It is a very difficult diagnosis, and I have known so many wonderful people that have passed. I try to give each patient the attention they deserve, and get them scheduled as soon as possible. Our team is constantly brainstorming solutions on the fly, and the knowledge and the experience the nurses that I work with have is such an inspiration to witness every day.”

Elizabeth A. Rosenberg, DNP, MA, RN, OCN, CNML, Clinical Program Manager at Smilow Fairfield and Trumbull, commented, “Kathy is one of the most dedicated employees that I have ever had the privilege to work with. She is always willing to help in any capacity to ensure a positive patient experience for everyone we care for.”

#OUTOFTHEBLUETHANKS to Katie Racicot, MPH!

Yale Cancer Center & Smilow Cancer Hospital’s #OUTOFTHEBLUETHANKS recently recognized Katie Racicot, MPH, a Clinical Research Assistant from the Clinical Trials Office. Within her role as Clinical Research Assistant in the Clinical Trials Office, Katie has gone above and beyond to support three Disease Aligned Research Teams during your care of our patients.

We are pleased to welcome Julie Jung Kang, MD, PhD to the Department of Therapeutic Radiology. Dr. Kang will join the Smilow Radiation Oncology team in Trumbull in April from Memorial Sloan Kettering Cancer Center (MSKCC), where she is currently an Assistant Attending of Radiation Oncology.

Dr. Kang is a graduate of Yale University. She received her medical degree in 2010 from Keck School of Medicine of USC where she also received her PhD in Systems Biology. At MSKCC, she has led clinical trials in treatment de-escalation and immunotherapy in head and neck cancer. Her clinical and research interests include head and neck cancer and genitourinary malignancies.
Aligned Research Teams during a period of staffing shortages. In addition to this, she has taken an active role in training and mentoring new staff who have joined the department. Katie tackles each new request with grace and enthusiasm, ensuring the work she outputs is of the highest quality. Katie's efforts have allowed the team to successfully meet database locks, be appropriately prepared for audits, and keep all requirements fulfilled during times of challenges. Her contributions to the team and the Clinical Trials Office are invaluable. Thank you, Katie!

Yale Cancer Center & Smilow Cancer Hospital’s #OUTOFTHEBLUETHANKS program is a staff recognition initiative to show appreciation to employees who have exemplified an above-and-beyond effort or an outstanding contribution to the team. If you are interested in submitting a nomination, please complete this nomination form and return it to the Director’s Office c/o Anna Raso.

Recent Publications


Read More


Read More


Read More


Read More

New research led by @QinYan1 in @ScienceTM explores a new path to target the CECR2 gene and treat advanced triple-negative #breastcancer.

Please join us today at Noon for Grand Rounds. Dr. Kurt Schalper reports on the #lungcancer microenvironment in immune evasion & therapeutic resistance. @JSheltzer discusses targeted therapies & clinical trials.

A new survey led by @LisaFucito in @CAPR_AACR identified barriers to tobacco treatment & differences by race/ethnicity among patients screened for #lungcancer.

Tune in tonight at 7:30pm to Yale Cancer Answers to hear from @SanginiSheth about the current rates of #HPV-vaccination in young adults, and areas that still need improvement. Listen live on @wnpr or download our podcast from iTunes.

"If it were not for you giving all that blood, I would not be here."—Nicole Donzello, a patient @SmilowCancer, talks about the need for blood donations to help patients w/cancer at a news conference @YNHH w/@CTRedCross.
D’Addario J.
Endometrial Cancer

Guha A, Fradley MG, Dent SF, Weintraub NL, Lustberg MB, Alonso A, Addison D.
Incidence, Risk Factors, And Mortality Of Atrial Fibrillation In Breast Cancer: A SEER-Medicare Analysis
European Heart Journal, 43(4):300-312.

Damast S, Chino J.
Secondary Prevention, Not Secondary Importance: Embracing Survivorship Concerns and HRT After Cervical Cancer Radiation Therapy

Pauken KE, Lagattuta KA, Lu BY, Lucca LE, Daud AI, Hafler DA, Kluger HM, Raychaudhuri S, Sharpe AH.
TCR-sequencing in Cancer And Autoimmunity: Barcodes And Beyond
Trends in Immunology, Online ahead of print.

Incremental Spending Associated with Low-Value Treatments in Older Women with Breast Cancer
Annals of Surgical Oncology, 29(2):1051-1059

Lokeshwar SD, Syed JS, Segal D, Rahman SN, Sprenkle PC.
Optimal Use of Tumor-Based Molecular Assays for Localized Prostate Cancer
Current Oncology Reports, Online ahead of print.

McQuaid DC, Panse G, Wang WL, Pinkus GS, Katz SG, Xu ML.
Global Assessment of IRF8 as a Novel Cancer Biomarker
Human Pathology, Online ahead of print.

Chow R, Navari RM, Terry B, DeAngelis C, Prsic EH.
Olanzapine 5 mg vs 10 mg for the Prophylaxis Of Chemotherapy-Induced Nausea And Vomiting: A Network Meta-Analysis
Supportive Care in Cancer, 30(2):1015-1018.

Bold KW, Cannon S, Ford BB, Neveu S, Sather P, Toll BA, Fucito LM.
Examining Tobacco Treatment Perceptions and Barriers Among Black vs. Non-Black Adults Attending Lung Cancer Screening
Cancer Prevention Research, Online ahead of print.


Billingsley KG. The Next Step in Tumor Board Evolution: Optimizing Care Coordination and Integration : Editorial on "Integrating a Disease-Focused Tumor Board as a Delivery-of-Care Model to Expedite Treatment Initiation for Patients with Liver Malignancies". Annals of Surgical Oncology, Online ahead of print.


Lerner BA, Xicola RM, Rodriguez NJ, Karam R, Llor X. Simplified and more sensitive criteria for identifying individuals with pathogenic CDH1 variants. Journal of Medical Genetics, Online ahead of print.

Mabey JG, Cornman-Homonoff J, Madoff DC. Balloon-assisted Radioembolization Via The Proper Hepatic Artery To Treat A Left Liver Hepatocellular Carcinoma And Portal Vein Tumor Thrombus With An Inaccessible Left Hepatic Artery: A Case Report. Clinical Imaging, 82:244-250. Read More


Shallis RM, Gore SD. Agent Orange and Dioxin-Induced Myeloid Leukemia: A Weaponized Vehicle Of Leukemogenesis. Leukemia & Lymphoma, Online ahead of print. Read More


Expression of the Transcription Factor PU.1 Induces The Generation Of Microglia-Like Cells In Human Cortical Organoids

Funding and Award Opportunities

Pediatric Oncology Student Training (POST) Program
As part of the Alex’s Lemonade Stand Foundation (ALSF), the POST Program is designed for undergraduate, graduate, and medical students who have an interest in pediatric oncology research and would like to experience the field firsthand. Students train with a pediatric oncology research mentor. Students may join a research project underway in a mentor’s lab or begin an original investigation with the mentor.

Application Deadline: February 21, 2022

Bladder Cancer Advocacy Network (BCAN) Early Career Investigator Awards
- **Young Investigator Award 2022**: This award is for outstanding early-career scientists and clinical cancer research investigators with a demonstrated commitment to improving the understanding and treatment of bladder cancer and/or upper tract urothelial cancer research. [https://bcan.org/wp-content/uploads/2022/01/2021_01_04_YIA-Guidelines-2022_FINAL.pdf](https://bcan.org/wp-content/uploads/2022/01/2021_01_04_YIA-Guidelines-2022_FINAL.pdf)

Application Deadlines: February 22, 2022

2022 LUNGevity Foundation Lung Cancer Translational Research Awards
- **Career Development Award Program**- created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas.
- **Veterans Affairs Research Scholar Award Program**- supports fellows or junior faculty interested in lung cancer research within the Department of Veterans Affairs.
- **Health Equity and Inclusiveness Junior Investigator Award Program**- supports physician-scientists interested in conducting lung cancer clinical research and bridging health disparities by engaging underserved communities or underrepresented minorities.
- **Health Equity and Inclusiveness Research Fellow Award Program**- supports fellows interested in translational lung cancer research who belong to underrepresented minorities in STEM.
- **Pierre Massion Young Investigator Award for Early Detection Research**- a new award that will support a young investigator from underrepresented minorities in STEM who is interested in early detection of lung cancer.

Letters of Intent Due: February 23, 2022

MB&B Seminar
February 14; 4:00 PM
Microaggressions: How to They Impact the Academic Environment for Trainees
Darin Latimore, MD
Learn More

Yale Cancer Center Grand Rounds
February 15; 12:00 PM
A New Deal for Cancer
Charles Fuchs, MD, MPH & Abbe Gluck
Learn More

YSHP/CDE 526 Seminar in Chronic Disease Epidemiology
February 15; 12:00 PM
Screening for Prostate Cancer: Applying Lessons from Prostate Cancer Management to Improve the Quality of Early Detection
Michael S. Leapman, MD
Learn More

Neuroendocrine Conference
February 16; 4:00 PM
Basic P2P Review
Carolina Gonzalez-Lopez and Robert Weingold
Learn More

Pathology Grand Rounds
February 17; 12:30 PM
Intersection of Oncology and Molecular Pathology
Joanna Gibson, MD, PhD
Learn More

Pharmacology Seminar Series
February 17; 12:30 PM
Signaling, Illuminated: Moving Proteins and Assembling Organelles to Crack the Signaling Code
Dr. Jared Toettcher
Learn More

Yale Pulmonary, Critical Care & Sleep Medicine Grand Rounds
February 16; 3:00 PM
HONOR Lecture: Twenty Years of Progress in the Treatment of Non-Small Cell Lung Cancer: Targeted Therapy, Immunotherapy and the Yale SPORE
Roy S. Herbst, MD, PhD
Learn More

Yale Center for Immuno-Oncology Seminar
Yale Liver Center Pilot Grants
Funded through their NIH/NIDDK P30 Liver Center grant, these grants are to fund new liver-related research that should lead to future R01-type funding or other support.
**Application Deadline:** February 25, 2022

International Lung Cancer Foundation Research Grants
Adequate research funding is key to furthering developments in lung cancer treatment. Through partnering with foundations, non-profits, corporations and individual donors, the International Lung Cancer Foundation (ILCF) provides multiple funding opportunities each year to facilitate scientific advances and save lives. Before beginning your application, please review each section of this website to learn more about our available grants and our process.
**Application Deadline:** February 28, 2022

Early K99/R00 Funding Opportunity Announcements
The NCI just reissued “early K99/R00” - NCI Pathway to Independence Award for Outstanding Early-Stage Postdoctoral Researchers FOAs that might be of interest to some postdoctoral fellows.
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
**Application Deadlines:** February 28, 2022

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)
The purpose of this award is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent tenure-track (or equivalent) faculty positions.
**Application Deadline:** February 28, 2022

NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of gaining new scientific information.

**Seminar**
February 17; 4:00 PM
*Mechanisms behind CAR T Cells*
Marcela Maus, MD, PhD
Learn More

**Center for GI Cancers Weekly Seminar**
February 17; 4:15 PM
Daniel M. Halperin, MD
Learn More

__Share your news!__
Please submit your recent publications, awards, and grant announcements to:
Renee Gaudette
Director, Public Affairs and Communications
biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.

**Application Deadline:** February 28, 2022

Read More

**JH Milstone Fund 2022**
This award is to support early-stage investigators and innovative research that improves understanding of bleeding, thrombosis or thrombolysis. The research can focus on the genetics, biochemistry or cell biology of coagulation or thrombolysis or on the causes, pathogenesis, diagnosis or treatment of bleeding and clotting disorders. In the absence of preliminary data, appropriate mentors and/or collaborators are important.

**Letter of Intent Due:** March 1, 2022

Further information: contact Richard.Carr@yale.edu

**DeLuca Career Development Award 2022**
The purpose of this career development award is to provide early career clinical or laboratory-based investigators in Hematology, the opportunity to focus on research to advance patient care, therapies, and outcomes and with the ultimate goal to achieve independent support for their research from a national agency. For further information contact Richard.Carr@yale.edu

**Letter of Intent Due:** March 1, 2022

Read More

**JH Milstone Fund 2022**
This award is to support early-stage investigators and innovative research that improves understanding of bleeding, thrombosis or thrombolysis. The research can focus on the genetics, biochemistry or cell biology of coagulation or thrombolysis or on the causes, pathogenesis, diagnosis or treatment of bleeding and clotting disorders. In the absence of preliminary data, appropriate mentors and/or collaborators are important.

**Letter of Intent Due:** March 1, 2022

Further information: contact Richard.Carr@yale.edu

**The Mark Foundation Endeavor Awards**
These awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.

**Letter of Intent Due:** March 1, 2022

Read More

**The Society for Immunotherapy of Cancer (SITC) Women in Cancer Immunotherapy Network (WIN) Leadership Institute**
SITC will be offering an in-person this summer on Aug. 1–2, 2022 in Seattle, WA. The program, championed by SITC Past President Lisa H. Butterfield, PhD, the society’s first female president, is a professional development and networking event that seeks to empower emerging female leaders in the cancer immunotherapy field.

This program will feature presentations from experienced female leaders, panel discussions allowing participants to ask questions and interact with these leaders and our distinguished program organizers, and in-person networking opportunities.
Breast Cancer Alliance: Exceptional Project Grants
BCA invites clinical doctors and research scientists, including post docs, at any stage of their careers whose primary focus is breast cancer to apply for an Exceptional Project Grant. This award recognizes creative, unique, and innovative research and is open to applicants at institutions throughout the contiguous United States. Only two nominees may be put forward by YCC.

Application Deadline: March 2, 2022
Read More

BMSF Diversity in Clinical Trials Career Development Program
The intent of this program is to increase diversity in clinical trials. The initiative is comprised of a Career Development Program for early-stage clinical investigators and a Clinical Investigator Pipeline Program (BMSF CIPP) for rising second-year medical students.

Application Deadline: March 15, 2022
Read More

U.S. and Low- and Middle-Income Country (LMIC) HIV-Associated Malignancy Research Centers
The purpose of this FOA is to support research on human immunodeficiency virus (HIV)-associated cancers in low- and middle-income countries (LMICs) through the formation of collaborative partnerships between investigators in the United States and investigators in LMICs.

Application Deadline: March 30, 2022
Read More

SITC FELLOWSHIPS for Early Career Scientists
SITC is dedicated to assisting investigators in advancing the science of immunotherapy and developing new therapeutic approaches. To further this goal, we are offering eight Fellowships and Technology Awards, totaling $680,000 in funding. These Fellowships and Technology Awards are only available to SITC members.

- Bristol Myers Squibb Postdoctoral Cancer Immunotherapy Translational Fellowship
- Amgen Cancer Immunotherapy in Hematologic Malignancies Fellowship
- AstraZeneca Immunotherapy in Lung Cancer Clinical Fellowship
- Merck Cancer Immunotherapy Clinical Fellowship
- Genentech Women in Cancer Immunotherapy Fellowship
- Nektar Therapeutics Equity and Inclusion in Cancer Immunotherapy Fellowship
- Mallinckrodt Pharmaceuticals Adverse Events in Cancer Immunotherapy Clinical Fellowship
- Natera ctDNA Immunotherapy Response Monitoring Fellowship and Technology Award

Application Deadline: April 5, 2022
Read More

Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61)
The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses.

Application Deadline: April 22, 2022
Advanced Development and Validation of Emerging Cancer Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community.

Application Deadline: April 22, 2022
Read More

Pew-Stewart Scholars for Cancer Research

The Pew-Stewart Scholars for Cancer Research supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer. The award provides $300,000 in flexible support—$75,000 per year for a four-year period.

Institutional Nomination Due: May 18, 2022
Read More

Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 and R21)

The purpose of these FOAs is to promote epidemiologic research investigating novel and innovative hypotheses on emerging risk factors (biological, environmental, and social) and their interplay with established risk factors (e.g., viral hepatitis) associated with the development of liver cancer (hepatocellular carcinoma and other histological subtypes) in the United States.

Application Deadline: June 16, 2022
Read More

Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01)

This FOA will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research.

Application Deadline: July 5, 2022
Read More